Gene profiling test identifies melanoma tumors likely to metastasize

Denver — In the battle against melanoma, a new test has shown that it can identify primary cutaneous melanomas that are likely to metastasize in patients who had negative sentinel lymph node biopsies (SLNB). Available since mid-2013, the product (DecisionDx-Melanoma, Castle Biosciences) uses gene expression profiling (GEP).

“SLNB is currently considered the strongest single prognostic parameter for melanoma,” according to study author Pedram Gerami, M.D., who presented the data at the 72nd Annual Meeting of the American Academy of Dermatology. He is associate professor of dermatology and director of melanoma research at the Northwestern Skin Cancer Institute, Northwestern University, Chicago.

In a recent head-to-head test, “GEP testing performed superiorly to SLNB in our data set,” he says.

Read the full story here. 

Know Your Risk


A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation